REG-Qube Research & Technologies LTD Form 8.3 - Primary Health Properties PLC
24/06/2025 12:30
For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250624:nBw7b6DPNa&default-theme=true
Form 8.3 - Primary Health Properties PLC
FORM 8.3
PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY
A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
Rule 8.3 of the Takeover Code (the “Code”)
1. KEY INFORMATION
(a) Full name of discloser: Qube Research & Technologies Limited
(b) Owner or controller of interests and short positions disclosed, if
different from 1(a):
The naming of nominee or vehicle companies is insufficient. For a trust, the
trustee(s), settlor and beneficiaries must be named.
(c) Name of offeror/offeree in relation to whose relevant securities this form Primary Health Properties PLC
relates:
Use a separate form for each offeror/offeree
(d) If an exempt fund manager connected with an offeror/offeree, state this
and specify identity of offeror/offeree:
(e) Date position held/dealing undertaken: 23-06-2025
For an opening position disclosure, state the latest practicable date prior to
the disclosure
(f) In addition to the company in 1(c) above, is the discloser making Assura PLC
disclosures in respect of any other party to the offer?
If it is a cash offer or possible cash offer, state “N/A”
2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE
If there are positions or rights to subscribe to disclose in more than one
class of relevant securities of the offeror or offeree named in 1(c), copy
table 2(a) or (b) (as appropriate) for each additional class of relevant
security.
(a) Interests and short positions in the relevant securities of the offeror or
offeree to which the disclosure relates following the dealing (if any)
Class of relevant security: 12.5p ordinary
Interests Short positions
Number % Number %
(1) Relevant securities owned and/or controlled: 0 0.00 0 0.00
(2) Cash-settled derivatives: 11,023,829 0.82 0 0.00
(3) Stock-settled derivatives (including options) and agreements to 0 0.00 0 0.00
purchase/sell:
11,023,829 0.82 0 0.00
TOTAL:
All interests and all short positions should be disclosed.
Details of any open stock-settled derivative positions (including traded
options), or agreements to purchase or sell relevant securities, should be
given on a Supplemental Form 8 (Open Positions).
(b) Rights to subscribe for new securities (including directors’ and other
employee options)
Class of relevant security in relation to which subscription right exists: 0
Details, including nature of the rights concerned and relevant percentages: 0
3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE
Where there have been dealings in more than one class of relevant securities
of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as
appropriate) for each additional class of relevant security dealt in.
The currency of all prices and other monetary amounts should be stated.
(a) Purchases and sales
Class of relevant security Purchase/sale Number of securities Price per unit (GBp)
(b) Cash-settled derivative transactions
Class of relevant security Product description Nature of dealing Number of securities Exercise price per unit (GBp)
e.g. call option
e.g. opening/closing a long/short position, increasing/reducing a long/short
position
12.5p ordinary equity swap decreasing a long position 5898 99.10
12.5p ordinary equity swap decreasing a long position 19131 99.15
12.5p ordinary equity swap decreasing a long position 16515 99.20
12.5p ordinary equity swap decreasing a long position 1993 99.45
12.5p ordinary equity swap decreasing a long position 195042 99.50
12.5p ordinary equity swap decreasing a long position 2000 100.00
12.5p ordinary equity swap decreasing a long position 1344 100.20
12.5p ordinary equity swap decreasing a long position 8369 100.30
12.5p ordinary equity swap decreasing a long position 7750 100.40
12.5p ordinary equity swap decreasing a long position 1734 100.70
12.5p ordinary equity swap decreasing a short position 3552 99.00
12.5p ordinary equity swap decreasing a short position 7138 99.10
12.5p ordinary equity swap decreasing a short position 6017 99.15
12.5p ordinary equity swap decreasing a short position 7036 99.20
12.5p ordinary equity swap decreasing a short position 4757 99.25
12.5p ordinary equity swap decreasing a short position 3730 99.30
12.5p ordinary equity swap decreasing a short position 9454 99.35
12.5p ordinary equity swap decreasing a short position 3775 99.40
12.5p ordinary equity swap decreasing a short position 5235 99.45
12.5p ordinary equity swap decreasing a short position 1815 99.60
12.5p ordinary equity swap decreasing a short position 1855 99.65
12.5p ordinary equity swap decreasing a short position 1965 99.90
12.5p ordinary equity swap decreasing a short position 7594 100.10
12.5p ordinary equity swap decreasing a short position 9114 100.20
12.5p ordinary equity swap decreasing a short position 1960 100.30
12.5p ordinary equity swap decreasing a short position 1687 100.60
12.5p ordinary equity swap decreasing a short position 3431 102.50
12.5p ordinary equity swap decreasing a short position 147 103.00
12.5p ordinary equity swap increasing a long position 14507 99.10
12.5p ordinary equity swap increasing a long position 168912 99.15
12.5p ordinary equity swap increasing a long position 1190327 99.20
12.5p ordinary equity swap increasing a long position 7615 99.23
12.5p ordinary equity swap increasing a long position 163022 99.25
12.5p ordinary equity swap increasing a long position 79446 99.30
12.5p ordinary equity swap increasing a long position 4950 99.35
12.5p ordinary equity swap increasing a long position 18601 99.40
12.5p ordinary equity swap increasing a long position 15887 99.45
12.5p ordinary equity swap increasing a long position 180936 99.50
12.5p ordinary equity swap increasing a long position 39113 99.55
12.5p ordinary equity swap increasing a long position 8971 99.60
12.5p ordinary equity swap increasing a long position 23508 99.65
12.5p ordinary equity swap increasing a long position 13986 99.70
12.5p ordinary equity swap increasing a long position 400 99.80
12.5p ordinary equity swap increasing a long position 5073 99.90
12.5p ordinary equity swap increasing a long position 18738 99.95
12.5p ordinary equity swap increasing a long position 20258 100.00
12.5p ordinary equity swap increasing a long position 17209 100.10
12.5p ordinary equity swap increasing a long position 75212 100.20
12.5p ordinary equity swap increasing a long position 182863 100.30
12.5p ordinary equity swap increasing a long position 126290 100.40
12.5p ordinary equity swap increasing a long position 70412 100.50
12.5p ordinary equity swap increasing a long position 29708 100.60
12.5p ordinary equity swap increasing a long position 22197 100.70
12.5p ordinary equity swap increasing a long position 4286 100.80
12.5p ordinary equity swap increasing a long position 172088 101.00
12.5p ordinary equity swap increasing a long position 849 103.00
(c) Stock-settled derivative transactions (including options)
(i) Writing, selling, purchasing or varying
Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit (GBp) Type Expiry date Option money paid/ received per unit
(GBp)
e.g. American, European etc.
(ii) Exercise
Class of relevant security Product description Exercising/ exercised against Number of securities Exercise price per unit
e.g. call option
0 0 0 0
0
(d) Other dealings (including subscribing for new securities)
Class of relevant security Nature of dealing Details Price per unit (if applicable)
e.g. subscription, conversion
0 0 0
0
4. OTHER INFORMATION
(a) Indemnity and other dealing arrangements
Details of any indemnity or option arrangement, or any agreement or
understanding, formal or informal, relating to relevant securities which may
be an inducement to deal or refrain from dealing entered into by the person
making the disclosure and any party to the offer or any person acting in
concert with a party to the offer:
Irrevocable commitments and letters of intent should not be included. If there
are no such agreements, arrangements or understandings, state “none”
None
(b) Agreements, arrangements or understandings relating to options or
derivatives
Details of any agreement, arrangement or understanding, formal or informal,
between the person making the disclosure and any other person relating to:
(i) the voting rights of any relevant securities under any option; or
(ii) the voting rights or future acquisition or disposal of any relevant
securities to which any derivative is referenced:
If there are no such agreements, arrangements or understandings, state
“none”
None
(c) Attachments
Is a Supplemental Form 8 (Open Positions) attached? NO
Date of disclosure: 24-06-2025
Contact name: Janice Falcao
Telephone number: 00442033140679
Public disclosures under Rule 8 of the Code must be made to a Regulatory
Information Service.
The Panel’s Market Surveillance Unit is available for consultation in
relation to the Code’s disclosure requirements on +44 (0)20 7638 0129. The
Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk
(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.thetakeoverpanel.org.uk%2F&esheet=54281474&newsitemid=20250624191816&lan=en-US&anchor=www.thetakeoverpanel.org.uk&index=1&md5=712121f2a0f8b78f863a365f6a38511e)
.
View source version on businesswire.com:
https://www.businesswire.com/news/home/20250624191816/en/
(https://www.businesswire.com/news/home/20250624191816/en/)
Qube Research & Technologies LTD
Copyright Business Wire 2025Recent news on Primary Health Properties
See all newsREG - Stock Exch Notice - Admission to Trading - 30/03/2026
AnnouncementREG - Primary Health Props - Issue of shares for Long Term Incentive Plan
AnnouncementREG - Primary Health Props - Annual Report 2025 and Notice of 2026 AGM
AnnouncementREG - Primary Health Props - Preliminary Results
AnnouncementREG - Primary Health Props - Director/PDMR Shareholding
Announcement